🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseLiver biopsy changes on semaglutide — looking for input

Liver biopsy changes on semaglutide — looking for input

Dr.GutHealth Sat, Oct 19, 2024 at 8:18 AM 29 replies 2,184 viewsPage 1 of 6
This thread is more than 19 months old. Information may be outdated. Consider searching for more recent discussions.
Dr.GutHealth
Senior Member
1,456
7,890
Mar 2024
Minnesota
Oct 19, 2024 at 8:18 AM#1

This gets cited here weekly, usually second-hand, so it is worth setting out what it does and does not establish.

Steady state is the thing most people miss. The terminal half-life is about a week, so every dose step takes four to five weeks to fully express itself. Judging a step at day ten is judging the ascent, not the plateau, and it is the single commonest reason people escalate before they needed to.

Where I think it is weakest: the population was selected and supported in ways a real cohort is not, so I would read the effect size as a ceiling rather than an expectation.

The bit I cannot resolve on my own is how much of the between-person variation is pharmacokinetic and how much is just adherence measured badly. Numbers rather than impressions, if you have them.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
45 15VanRx_Mike, steve_okc, dave_SLC and 42 others
Reply Quote Save Share Report
labquiet_amy
Senior Member
1,234
6,789
Mar 2024
Cambridge, MA
Oct 19, 2024 at 9:36 AM#2
Dr.GutHealth said:
Steady state is the thing most people miss.

That holds for the injectable. The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people quote them as if they were.

Last edited: Oct 19, 2024 at 11:36 AM
44 14HPLC_Greg, LibrarianMeg, bri_stats and 41 others
Reply Quote Save Share Report
pete_manc_UK
Senior Member
1,234
5,678
Mar 2024
Manchester, UK
Oct 19, 2024 at 10:54 AM#3
Dr.GutHealth said:
Steady state is the thing most people miss.

This is where I part company with the consensus forming above. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.

43 13FitDadDave, RunnerRach, TrialNerd_Beth and 40 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
Dr.ObesityLA
VIP Member
3,567
19,876
Dec 2023
Los Angeles, CA
Oct 19, 2024 at 12:12 PM#4

Taking the question as asked, rather than the general version of it. The mechanism that matters here is not stomach emptying, it is central. GLP-1 receptor agonism in the arcuate nucleus stimulates POMC neurons and suppresses AgRP/NPY signalling, which is why the effect is appetite and food salience rather than physical fullness. Delayed gastric emptying largely tachyphylaxes over the first months; the appetite effect does not.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

Last edited: Oct 19, 2024 at 1:12 PM
42 12chris_chi24, tampaLisa73, KarenAZ_mom and 39 others
Reply Quote Save Share Report
amy_econ_NJ
Member
567
2,567
May 2024
Princeton, NJ
Oct 19, 2024 at 7:46 PM#5
labquiet_amy said:
The oral formulation has different absorption behaviour and the dose numbers are not interchangeable, which is worth saying out loud because people…

Agreed, though "tolerable" needs defining. A dose you tolerate by eating almost nothing is not tolerated, it is being paid for somewhere else — usually in lean mass, sometimes in adherence three months later.

41 11NurseLeah_Nash, gary_naperville, sean_dublin and 38 others
Reply Quote Save Share Report
1236

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register